Document is current
Any future updates will be listed below
-
Authors
Becilli, Marco https://orcid.org/0000-0002-8874-4092
Metzler, Markus https://orcid.org/0000-0002-4523-1676
Bracaglia, Claudia https://orcid.org/0000-0002-9834-9619
Nicolai, Rebecca https://orcid.org/0000-0003-4298-0628
Krickau, Tobias
Del Bufalo, Francesca https://orcid.org/0000-0001-9643-3465
Rosignoli, Chiara
Marasco, Emiliano
Naumann-Bartsch, Nora https://orcid.org/0000-0001-5606-9822
Messia, Virginia
Merli, Pietro https://orcid.org/0000-0001-6426-4046
Pagliara, Daria
Algeri, Mattia
Secinaro, Aurelio https://orcid.org/0000-0002-2611-8061
Cefalo, Maria Giuseppina
Diomedi Camassei, Francesca
Bertaina, Valentina
Sinibaldi, Matilde
Insalaco, Antonella
Aigner, Michael
Leone, Giovanna
Li Pira, Giuseppina
Gunetti, Monica
Berg, Stefan
De Angelis, Biagio https://orcid.org/0000-0002-7938-737X
Völkl, Simon https://orcid.org/0000-0003-2193-3048
Hanssens, Linda
Müller, Fabian https://orcid.org/0000-0001-5487-5839
Mackensen, Andreas https://orcid.org/0000-0002-0685-4483
Quintarelli, Concetta
Schett, Georg https://orcid.org/0000-0001-8740-9615
De Benedetti, Fabrizio https://orcid.org/0000-0001-8749-8232
Locatelli, Franco https://orcid.org/0000-0002-7976-3654
- License Information
-
More Information
Article History
Received: 19 August 2025
Accepted: 18 December 2025
First Online: 5 February 2026
Competing interests
: M.M. has participated in advisory boards for Novartis. T.K. has received consulting fees from Novartis and Pfizer; speaker honoraria from Novartis, Pfizer and Kyowa Kirin; and meeting support from Pfizer, Novartis and AbbVie. P.M. reports personal fees from Sobi, Miltenyi and Amgen. M. Aigner has received research grants from Miltenyi Biotec and Kyverna; consulting fees from Miltenyi Biotec; speaker honoraria from Miltenyi Biotec and Raumedic; expert testimony payments from RUHR‑IP; travel support from Miltenyi Biotec and material support from Miltenyi Biotec. S.V. has received research support from the Interdisciplinary Center for Clinical Research at University Hospital Erlangen‑Nuremberg (grant D43). L.H. is an employee of Miltenyi Biomedicine. F.M. has received research grants from Kite/Gilead; consulting fees from AbbVie, ArgoBio, AstraZeneca, Bristol Myers Squibb, CRISPR Therapeutics, Janssen, Kite and Novartis; speaker honoraria from AbbVie, ArgoBio, AstraZeneca, Bristol Myers Squibb, CRISPR Therapeutics, Janssen, Kite, Kyverna, Miltenyi Biomedicine, Novartis and Sobi; has served on an advisory board for Bristol Myers Squibb and received research funding from Deutsche Krebshilfe (grant 0113695). A.M. has received research grants from Miltenyi Biomedicine and Kyverna; consulting fees from BMS/Celgene, Kite/Gilead, Novartis, BioNTech, Miltenyi Biomedicine and Century Therapeutics; speaker honoraria from BMS/Celgene, Kite/Gilead, Novartis and Miltenyi Biomedicine; and meeting support from AbbVie and Janssen. G.S. has received speaker honoraria from Novartis, Bristol Myers Squibb, Kyverna and Cabaletta. F. De Benedetti declares unrestricted research grants from Sobi, Sanofi, Regeneron, Roche, Elixiron and Novartis; participation on the Data Safety Monitoring Board for Regeneron and consulting fees from Sobi, Novartis and Apollo. F.L. serves on the scientific advisory board of Amgen, Novartis, Sanofi and Vertex; and speaker’s bureau for Miltenyi Biomedicine, Amgen, Novartis, Bristol Myers Squibb, Gilead, MEDAC and Sobi. The other authors declare no competing interests.
